載入...
Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors
BACKGROUND. Immune‐checkpoint inhibitors (ICIs) are now standard of care for advanced non‐small cell lung cancer (NSCLC). Unfortunately, many patients experience immune‐related adverse events (irAEs), which are usually mild and reversible, but they require timely management and may be life threateni...
Na minha lista:
| 發表在: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693718/ https://ncbi.nlm.nih.gov/pubmed/31015312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0563 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|